FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220783634> ?p ?o ?g. }

• W4220783634 endingPage "2467" @default.
• W4220783634 startingPage "2458" @default.
• W4220783634 abstract "Subset analyses from phase III evaluation of epidermal growth factor receptor inhibition (EGFRi) suggest improved outcomes in patients with EGFR-amplified gastroesophageal adenocarcinoma (GEA), but large-scale analyses are lacking. This multi-institutional analysis sought to determine the role of EGFRi in the largest cohort of patients with EGFR-amplified GEA to date.A total of 60 patients from 15 tertiary cancer centers in six countries met the inclusion criteria. These criteria required histologically confirmed GEA in the metastatic or unresectable setting with EGFR amplification identified by using a Clinical Laboratory Improvement Amendments-approved assay, and who received on- or off-protocol EGFRi. Testing could be by tissue next-generation sequencing, plasma circulating tumor DNA next-generation sequencing, and/or fluorescence in situ hybridization performed by a Clinical Laboratory Improvement Amendments approved laboratory. Treatment patterns and outcomes analysis was also performed using a deidentified clinicogenomic database (CGDB).Sixty patients with EGFR-amplified GEA received EGFRi, including 31 of 60 patients (52%) with concurrent chemotherapy. Across treatment lines, patients achieved a 43% objective response rate with a median progression-free survival of 4.6 months (95% CI, 3.5 to 6.4). Patients receiving EGFRi in first-, second-, and third-line therapy achieved a median overall survival of 20.6 months (95% CI, 13.5 to not reached [NR]), 9 months (95% CI, 7.9 to NR), and 8.4 months (7.6 to NR), respectively. This survival far exceeded the 11.2-month (95% CI, 8.7 to 14.2) median overall survival from first-line initiation of non-EGFRi therapy in patients with EGFR-amplified GEA in the CGDB. Despite this benefit, analysis of the CGDB (January 2011-December 2020) suggests that only 5% of patients with EGFR-amplified GEA received EGFRi.Patients with EGFR-amplified GEA derive significant benefit from EGFRi. Further prospective investigation of EGFRi in a well-selected patient population is ongoing in an upcoming trial of amivantamab in EGFR and/or MET amplified GEA." @default.
• W4220783634 created "2022-04-03" @default.
• W4220783634 creator A5009303158 @default.
• W4220783634 creator A5010010203 @default.
• W4220783634 creator A5011888674 @default.
• W4220783634 creator A5015799240 @default.
• W4220783634 creator A5017122759 @default.
• W4220783634 creator A5019406140 @default.
• W4220783634 creator A5019473289 @default.
• W4220783634 creator A5019892202 @default.
• W4220783634 creator A5022835462 @default.
• W4220783634 creator A5025295638 @default.
• W4220783634 creator A5031217394 @default.
• W4220783634 creator A5038253545 @default.
• W4220783634 creator A5038396374 @default.
• W4220783634 creator A5042265453 @default.
• W4220783634 creator A5045086331 @default.
• W4220783634 creator A5045756365 @default.
• W4220783634 creator A5045865889 @default.
• W4220783634 creator A5047974691 @default.
• W4220783634 creator A5048681236 @default.
• W4220783634 creator A5059855583 @default.
• W4220783634 creator A5062019987 @default.
• W4220783634 creator A5062748030 @default.
• W4220783634 creator A5064391478 @default.
• W4220783634 creator A5064495942 @default.
• W4220783634 creator A5068026508 @default.
• W4220783634 creator A5071611972 @default.
• W4220783634 creator A5074882255 @default.
• W4220783634 creator A5079437223 @default.
• W4220783634 creator A5086626483 @default.
• W4220783634 creator A5090604653 @default.
• W4220783634 date "2022-08-01" @default.
• W4220783634 modified "2023-10-18" @default.
• W4220783634 title "Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience" @default.
• W4220783634 cites W1909198384 @default.
• W4220783634 cites W1973840209 @default.
• W4220783634 cites W1977247044 @default.
• W4220783634 cites W1988442083 @default.
• W4220783634 cites W2007513598 @default.
• W4220783634 cites W2020404157 @default.
• W4220783634 cites W2049309222 @default.
• W4220783634 cites W2050211354 @default.
• W4220783634 cites W2090334782 @default.
• W4220783634 cites W2100490225 @default.
• W4220783634 cites W2111237964 @default.
• W4220783634 cites W2134519717 @default.
• W4220783634 cites W2152362765 @default.
• W4220783634 cites W2160981405 @default.
• W4220783634 cites W2165411051 @default.
• W4220783634 cites W2570401594 @default.
• W4220783634 cites W2618723848 @default.
• W4220783634 cites W2758471954 @default.
• W4220783634 cites W2763498516 @default.
• W4220783634 cites W2767612092 @default.
• W4220783634 cites W2793114790 @default.
• W4220783634 cites W2793364080 @default.
• W4220783634 cites W2809244864 @default.
• W4220783634 cites W2891909134 @default.
• W4220783634 cites W2897154408 @default.
• W4220783634 cites W2898359687 @default.
• W4220783634 cites W2901467300 @default.
• W4220783634 cites W2914997554 @default.
• W4220783634 cites W2938929416 @default.
• W4220783634 cites W2969377494 @default.
• W4220783634 cites W3020451509 @default.
• W4220783634 cites W3024911178 @default.
• W4220783634 cites W3082736986 @default.
• W4220783634 cites W3090241359 @default.
• W4220783634 cites W3100339258 @default.
• W4220783634 cites W3101423836 @default.
• W4220783634 cites W3108411734 @default.
• W4220783634 cites W3126578253 @default.
• W4220783634 cites W3128646645 @default.
• W4220783634 cites W3147820834 @default.
• W4220783634 cites W3168362067 @default.
• W4220783634 cites W3170632459 @default.
• W4220783634 cites W3171517418 @default.
• W4220783634 cites W4200595129 @default.
• W4220783634 doi "https://doi.org/10.1200/jco.21.02453" @default.
• W4220783634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35349370" @default.
• W4220783634 hasPublicationYear "2022" @default.
• W4220783634 type Work @default.
• W4220783634 citedByCount "5" @default.
• W4220783634 countsByYear W42207836342022 @default.
• W4220783634 countsByYear W42207836342023 @default.
• W4220783634 crossrefType "journal-article" @default.
• W4220783634 hasAuthorship W4220783634A5009303158 @default.
• W4220783634 hasAuthorship W4220783634A5010010203 @default.
• W4220783634 hasAuthorship W4220783634A5011888674 @default.
• W4220783634 hasAuthorship W4220783634A5015799240 @default.
• W4220783634 hasAuthorship W4220783634A5017122759 @default.
• W4220783634 hasAuthorship W4220783634A5019406140 @default.
• W4220783634 hasAuthorship W4220783634A5019473289 @default.
• W4220783634 hasAuthorship W4220783634A5019892202 @default.
• W4220783634 hasAuthorship W4220783634A5022835462 @default.
• W4220783634 hasAuthorship W4220783634A5025295638 @default.
• W4220783634 hasAuthorship W4220783634A5031217394 @default.

• next